Days of written notice needed in order to terminate the asset purchase agreement.

No definition available.

Name:	mgtx_AgreementTerminationPeriodDaysWrittenNotice
Namespace Prefix:	mgtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Funding received from the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_AssetPurchaseAgreementFundingReceived
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Initial funding received under Asset Purchase Agreement reclassified under provisions of new license agreement.

+ References

No definition available.

+ Details

Name:	mgtx_AssetPurchaseAgreementFundingReclassified
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum contingent funding available under the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_ContingentFundingAvailable
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total contract price of license agreement.

+ References

No definition available.

+ Details

Name:	mgtx_ContractPriceOfLicenseAgreement
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

No definition available.

+ Details

Name:	mgtx_DeferredRevenueRecognizedDuringPeriod
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of gain (loss) on the sale of non-financial assets.

+ References

No definition available.

+ Details

Name:	mgtx_GainLossOnSaleOfNonfinancialAssets
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Initial duration period of the asset purchase agreement.

+ References

No definition available.

+ Details

Name:	mgtx_InitialAgreementPeriodDuration
Namespace Prefix:	mgtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

No definition available.

+ Details

Name:	mgtx_LicenseRevenueFromRelatedParties
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone funding received and allocated to performance obligation for commercial supply of RPGR product.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingAllocatedToCommercialSupplyOfRpgrProduct
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received and allocated to performance obligation for manufacturing technology transfer.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingAllocatedToManufacturingTechnologyTransfer
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received and allocated to performance obligation for process performance qualification (PPQ) services.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingAllocatedToProcessPerformanceQualificationServices
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received and allocated to performance obligation for sale of nonfinancial assets.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingAllocatedToSaleOfNonfinancialAssets
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the completion of certain specified development services for the drug product for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForDevelopmentOfDrugProducts
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the completion of certain specified development services for the drug substance for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForDevelopmentOfDrugSubstances
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the achievement of the initiation of the extension study for the Phase 3 LUMEOS clinical trial for the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForExtensionOfClinicalTrials
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the regulatory approval of a Janssen-selected manufacturing facility in each of the United States and European Union for commercial manufacture of the RPGR Product in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForRegulatoryApproval
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the first commercial sale of an RPGR Product in at least one of the United Kingdom, France, Germany, Spain and Italy in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForSaleOfDrugProductsInUkFranceGermanySpainAndItaly
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the first commercial sale of an RPGR Product in the United States in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForSaleOfDrugProductsInUnitedStates
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received for the transfer of certain manufacturing technology for drug substance and drug product from the Company to Janssen in connection with the Company's asset purchase agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingForTransferOfManufacturingTechnology
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone funding received from the Company's collaboration agreement with Janssen Pharmaceuticals.

+ References

No definition available.

+ Details

Name:	mgtx_MilestoneFundingReceived
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Offsetting credit for transition services in determining contract price under license agreement.

+ References

No definition available.

+ Details

Name:	mgtx_OffsettingCreditForTransitionServices
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement contract price allocated to performance obligation for commercial supply of RPGR product.

+ References

No definition available.

+ Details

Name:	mgtx_PerformanceObligationForCommercialSupplyOfRpgrProduct
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement contract price allocated to performance obligation for manufacturing technology transfer.

+ References

No definition available.

+ Details

Name:	mgtx_PerformanceObligationForManufacturingTechnologyTransfer
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement contract price allocated to performance obligation for process performance qualification (PPQ) services.

+ References

No definition available.

+ Details

Name:	mgtx_PerformanceObligationForProcessPerformanceQualificationServices
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

License agreement contract price allocated to performance obligation for sale of nonfinancial assets.

+ References

No definition available.

+ Details

Name:	mgtx_PerformanceObligationForSaleOfNonfinancialAssets
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of income recognized from deferred related-party revenues.

+ References

No definition available.

+ Details

Name:	mgtx_RecognizedRelatedPartyDeferredRevenue
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Related-party deferred revenue reclassified under provisions of new license agreement.

+ References

No definition available.

+ Details

Name:	mgtx_RelatedPartyDeferredRevenueReclassified
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

+ References

No definition available.

+ Details

Name:	mgtx_ServiceRevenueFromRelatedParties
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Variable consideration included in provisions of new license agreement.

+ References

No definition available.

+ Details

Name:	mgtx_VariableConsiderationForServices
Namespace Prefix:	mgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_CommonStockSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

The cash outflow for cost incurred directly with the issuance of an equity security.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-15

+ Details

Name:	us-gaap_PaymentsOfStockIssuanceCosts
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483326/850-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481990/310-10-45-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

+ Details

Name:	us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=mgtx_JanssenPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=mgtx_ServiceRevenueRelatedPartyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mgtx_AssetPurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=mgtx_LicenseAgreementUclbRpgrMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Related Party Transactions - Collaboration and License Agreements (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 20, 2023	Dec. 31, 2023	Mar. 31, 2024	Dec. 31, 2025	Dec. 31, 2024
Related Party Transaction [Line Items]
Common stock, shares issued				81,120,931	78,397,380
Offering costs				$ 39	$ 2,516
Shares issued to related party				81,120,931	78,397,380
License revenue - related party				$ 74,991
Service revenue - related party				6,400	$ 33,279
Gain on sale of nonfinancial assets					28,434
Other Income
Related Party Transaction [Line Items]
Gain on sale of nonfinancial assets					28,400
Janssen Pharmaceuticals Inc \| Collaboration Agreement \| Service revenue - related party
Related Party Transaction [Line Items]
Service revenue - related party				6,400	33,300
Deferred revenue recognized as service revenue during the period				2,600	14,000
Deferred revenue - related party recognized				2,600	14,000
Janssen Pharmaceuticals Inc \| Asset Purchase Agreement
Related Party Transaction [Line Items]
Deferred revenue recognized as service revenue during the period				2,635
Initial agreement term	4 years
Written days-notice to terminate agreement	90 days
Milestone funding					$ 60,000
Non-refundable upfront cash funding	$ 65,000
Contingent funding available	350,000
Milestone funding for extension of RPGR product clinical trials			$ 50,000	50,000
Milestone funding for development of drug substances	10,000			10,000
Milestone funding for development of drug products	5,000
Milestone funding for sale of drug products in the US	175,000
Milestone funding for sale of drug products in the UK, France, Germany, Spain and Italy	75,000
Milestone funding for transfer of manufacturing technology	25,000
Milestone funding upon regulatory approval	10,000
Asset purchase agreement funding included in contract price of license agreement				5,800
Milestone funding allocated to process performance qualification services				1,600
Milestone funding allocated to commercial supply of RPGR product				3,800
Milestone funding allocated to manufacturing technology transfer				15,600
Milestone funding allocated to sale of nonfinancial assets				$ 29,000
Janssen Pharmaceuticals Inc \| UCLB RPGR License Agreement
Related Party Transaction [Line Items]
Deferred revenue - related party included in contract price of license agreement	30,600
Variable consideration for services included in contract price of license agreement	1,800
Asset purchase agreement funding included in contract price of license agreement	65,000
Contract price of license agreement	$ 92,300	$ 92,300
Offsetting credit for transition services		5,100
Performance obligation for process performance qualification services		2,900
Performance obligation for commercial supply of RPGR product		6,900
Performance obligation for manufacturing technology transfer		28,700
Performance obligation for sale of nonfinancial assets		$ 53,800